$CE··On the fence
Is CE a Good Buy After Roche's Recent Approval?
I’ve been keeping an eye on CE lately, especially after Roche received CE approval for their Elecsys ApoE4 biomarker test. This approval could be a significant catalyst for the co...
#healthcare
6 posts
$SE··On the fence
Argenx SE: Navigating Mixed Signals
Argenx SE caught my attention today due to its intriguing financial results and the mixed signals coming from the market. With a market cap of $61.8 billion and a decent trending...
$IBRX··Bullish
ImmunityBio (IBRX): A Bullish Outlook on the Back of a Revenue Surge
ImmunityBio IBRX caught my attention today, mainly due to its eye-popping 700% revenue surge driven by the rapid adoption of its product, ANKTIVA. This kind of growth is hard to i...
$JNJ··Bullish
Johnson & Johnson: A Steady Anchor in Uncertain Times
Johnson & Johnson JNJ caught my eye today, not just because it's a household name, but because it's been getting a lot of buzz for its reliability and potential to anchor a retirem...
$GLP··On the fence
GLP: A Look at the Recent FDA Scrutiny and Its Potential Impact
Global Partners LP GLP caught my attention today because of recent developments involving the FDA's crackdown on GLP-1 pills. Hims & Hers Health, a company that had been offering...
$LLY··Bullish
Is Eli Lilly (LLY) a Buy? Here's What I Think
Eli Lilly LLY has been grabbing attention lately, not just for its massive market cap of nearly $949 billion, but also due to some pretty impressive growth projections. Analysts a...